Artelo Biosciences Files to Effect 1-for-3 Reverse Stock Split to Boost Share Price
ARTL is trading near its 52-week low of $1.05 (3.8% below the low).
Summary
Artelo Biosciences will implement a 1-for-3 reverse stock split effective March 10, 2026, reducing outstanding shares to approximately 708,258, in an effort to improve marketability and maintain Nasdaq listing compliance.
Key Events · Corporate Governance and Compliance · ARTL
-
Reverse Stock Split Filed
The company filed a Certificate of Change with the State of Nevada to effect a 1-for-3 reverse stock split of its common stock.
-
Effective Date Set
The reverse stock split will be effective as of 12:01 a.m. Eastern Time on March 10, 2026.
-
Share Count Adjustment
Outstanding common shares will be reduced from 2,124,772 to approximately 708,258. Authorized common shares will also be proportionally reduced from 500,000,000 to 166,666,667.
-
Purpose for Split
The split is being effected to improve the marketability and liquidity of the common stock, directly addressing the need to maintain Nasdaq listing compliance following a recent extension and going concern warning.
Analysis · ARTL · Life Sciences
Artelo Biosciences has officially filed a Certificate of Change to implement a 1-for-3 reverse stock split, effective March 10, 2026. This action, which follows the company's recent 10-K filing disclosing a going concern warning and a Nasdaq listing extension, is a direct measure to increase the per-share price and improve marketability and liquidity, likely to meet Nasdaq's minimum bid price requirement. While the reverse split addresses an immediate compliance risk and theoretically boosts the stock price, it does not resolve the underlying operational or financial challenges. Investors should view this as a defensive maneuver, often indicative of a company struggling to maintain its listing and financial viability, especially given its current trading near 52-week lows.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $1.05 to $28.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.